Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus

Next Previous
Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapirolizumab pegol (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Acronyms RISE
  • Sponsors UCB

Most Recent Events

  • 15 Nov 2023 Results of post hoc analysis (from studies NCT01262365; n=249, NCT01261793; n=263 and NCT02804763; n=43) assessing Disease Course and Complement as Predictors of Response to Standard of Care Plus Placebo in Patients with SLE presented at the ACR Convergence 2023
  • 15 Nov 2023 Results of a post-hoc analysis assessing impact of DZP on B cell and type I IFN pathways using data from phase 2b RISE trial in SLE presented at the ACR Convergence 2023
  • 15 Nov 2023 Results of post hoc analysis evaluating the treatment effect of dapirolizumab pegol in subgroups of patients from the phase 2b RISE trial presented at the ACR Convergence 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top